Jak/Stat Pathway
SOCS2 Antibody
|
イイネ！(0)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2779S | 100 μL | 46,000 | |
|
SOCS2抗体製品一覧
2779 の推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
2779:
-
Immunoprecipitation
Western Blotting
| 用途（希釈倍率） | |
| ウエスタンブロッティング（1:1,000）、免疫沈降（1:100） |
| 特異性・感度 | |
| 内在性レベルのSOCS2 タンパク質を検出します。 |
| 使用抗原 | |
| ヒトのSOCS2 タンパク質のC末端周辺領域（合成ペプチド） |
Western Blotting
Western blot analysis of extracts from K562, A204 and PC12 cells using SOCS2 Antibody.
The SOCS (suppressor of cytokine signaling) family members are negative regulators of cytokine signal transduction that inhibit the Jak/Stat pathway (1-3). The SOCS family consists of at least 8 members including the originally identified protein CIS1 (cytokine-inducible SH2-containing protein) as well as SOCS1 through SOCS7. Each SOCS family member contains a central SH2 domain and a conserved carboxy-terminal motif designated as the SOCS box. These proteins are important regulators of cytokine signaling, proliferation, differentiation and immune responses.
Activity of SOCS2 has been predominantly linked to growth hormone (GH) and insulin-like growth factor 1 (IGF-1) signaling but may also contribute to several biological processes including metabolism, bone formation, neuronal development, cancer, infection and other cytokine-dependent pathways (5). SOCS2 is widely expressed in adult and fetal tissues and is induced upon cytokine treatment (5,6). A number of studies suggest that SOCS2 can have either a positive or negative effect on GH/cytokine signaling (7-10). Mice deficient in SOCS2 grow signficantly larger than normal littermates (8). SOCS2 binds to tyrosine-phosphorylated GH and IGF-1 receptors via its SH2 domain, suppressing their signaling (6,9). In addition, the SOCS box of SOCS2 binds to Elongin B and C leading to activity as a ubiquitin ligase, promoting the degradation of the receptors as well as other SOCS family members (11-13).
-
Alexander, W.S. et al. (1999) J Leukoc Biol 66, 588-92.
-
Chen, X.P. et al. (2000) Immunity 13, 287-90.
-
Hilton, D.J. et al. (1998) Proc Natl Acad Sci USA 95, 114-9.
-
Rico-Bautista, E. et al. (2006) Cytokine Growth Factor Rev 17, 431-9.
-
Starr, R. et al. (1997) Nature 387, 917-21.
-
Dey, B.R. et al. (1998) J Biol Chem 273, 24095-101.
-
Favre, H. et al. (1999) FEBS Lett 453, 63-6.
-
Metcalf, D. et al. (2000) Nature 405, 1069-73.
-
Greenhalgh, C.J. et al. (2002) J Biol Chem 277, 40181-4.
-
Greenhalgh, C.J. et al. (2005) J Clin Invest 115, 397-406.
-
Tannahill, G.M. et al. (2005) Mol Cell Biol 25, 9115-26.
-
Bullock, A.N. et al. (2006) Proc Natl Acad Sci U S A 103, 7637-42.
-
Piessevaux, J. et al. (2006) J Biol Chem 281, 32953-66.
PhosphoSitePlus®：
SOCS2